Krystal Biotech (KRYS) Competitors

Genmab A/S (NASDAQ:GMAB) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Is GMAB or KRYS more profitable?

Krystal Biotech has a net margin of 40.85% compared to Genmab A/S's net margin of 37.53%. Genmab A/S's return on equity of 21.03% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	37.53%	21.03%	16.98%
Krystal Biotech	40.85%	15.21%	13.81%

Which has more risk and volatility, GMAB or KRYS?

Genmab A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Which has higher earnings and valuation, GMAB or KRYS?

Genmab A/S has higher revenue and earnings than Krystal Biotech. Genmab A/S is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	5.16	$1.14B	$1.99	12.62
Krystal Biotech	$290.52M	15.02	$89.16M	$4.92	30.64

Do analysts recommend GMAB or KRYS?

Genmab A/S currently has a consensus price target of $37.60, suggesting a potential upside of 49.74%. Krystal Biotech has a consensus price target of $210.38, suggesting a potential upside of 39.54%. Given Genmab A/S's higher possible upside, equities research analysts clearly believe Genmab A/S is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of GMAB or KRYS?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media refer more to GMAB or KRYS?

In the previous week, Krystal Biotech had 14 more articles in the media than Genmab A/S. MarketBeat recorded 19 mentions for Krystal Biotech and 5 mentions for Genmab A/S. Krystal Biotech's average media sentiment score of 0.73 beat Genmab A/S's score of 0.66 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Genmab A/S on 10 of the 16 factors compared between the two stocks.